• Revenue up 136% to $8.5 million
• Loss increased 45% to $15.2 million, including $6.8 million in impairment expenses
• Gross margin improved to 59% due to reduced inventory obsolescence

Genetic Signatures Limited reported a 136% increase in revenue to $8.5 million for the half-year ended 31 December 2024, primarily driven by strong respiratory sales in Australia. International sales generated 9.4% of revenue, mainly to UK and European customers. The Group reported a loss of $15.2 million, which includes $6.8 million in impairment expenses. The loss excluding impairment expenses was $8.4 million. Gross margin on sales increased to 59% during the period, primarily due to decreased inventory obsolescence expenses. The company undertook a thorough assessment of the competitive landscape and customer needs, which led to the decision to cease the internal development of the Next Generation Instrument. Preparations for the commencement of commercial sales of the EasyScreenTM Gastrointestinal Parasite Detection Kit in the US are well underway, though initial sales have been delayed as customers complete their internal procurement processes. The company continues to build inventory and market awareness for the product. Australian sales were a key contributor to the half-year result, and the company is also building momentum in the EMEA region. The company's R&D efforts have focused on improving workflow and increasing automation. Allison Rossiter was appointed as the new CEO, and the company completed its planned Board renewal during the period.